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There is increasing promise that cellular immune response may be manipulated to combat cancer; however, it is
also clear that the immune response to cutaneous malignancy comprises different T cell activities that variably
inhibit or promote tumor development. Thus, a better understanding of each of these activities is crucial to more
effective clinical manipulation. To better characterize the protective anti-tumor effects of ab T cells, we examined
the growth of the transplantable squamous cell carcinoma (SCC) line, PDV, which is markedly inhibited in
immunocompetent versus ab T cell-deﬁcient mice. We show that the protective response is composed of CD8þ and
interferon-c (IFNc)-producing CD4þ cells, and that the most overt effects of these components on tumor growth in
situ are to provoke overt focal necroses and to decrease the stromal bed. Tumors growing in the presence of any of
these components also show reduced expression of Rae-1, a ligand for the activating NK receptor, NKG2D.
Collectively, these data illustrate which components of the ab T cell response against SCC have protective
potential, and indicate which aspects of tumor physiology may be most susceptible to their activities.
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In studies involving almost 4000 patients, collectively
suffering from melanoma and a broad variety of carcino-
mas, a positive correlation has been made between survival
and the presence of tumor-infiltrating lymphocytes (TIL)
(reviewed by Dunn et al, 2002). Consistent with this, organ
transplant recipients and other iatrogenically immunosup-
pressed patients demonstrate up to a 25-fold increased
relative risk of cutaneous malignancy (Euvrard et al, 1997;
Peto, 2001), with the greatest increase being in the de-
velopment of squamous cell carcinoma (SCC) (Peto, 2001;
Paul et al, 2003), that on average show greater progression
and lethality (Veness et al, 1999; Martinez et al, 2003).
Support for a role of the adaptive immune response in
regulating human cutaneous SCC is provided by TIL that
include TCRabþ , CD8þ , HLA-DRþ activated T cells that
are cytotoxic toward autologous tumor cells directly ex vivo
(Haeffner et al, 1997). At the same time, so-called kerato-
acanthomas, which represent well-differentiated SCCs
with a high probability of involution (Hodak et al, 1993;
Kerschmann et al, 1994), are substantially infiltrated by
activated CD4þ T cells when compared with invasive SCCs
(Patel et al, 1994). Building on such results, several clinical
approaches are being taken to enhance anti-tumor re-
sponses in patients (Banchereau et al, 2001; Dudley et al,
2002).
Nonetheless, the overt failure of the immune system to
prevent tumor formation in outwardly healthy individuals
and animals has often promoted the view that immunosur-
veillance of tumors is not generally applicable. An alter-
native interpretation that has recently gained experimental
support is that the immune response to tumors, like that to
infections, comprises a mixture of activities, the aggregate
effects of which may not always be protective. Thus,
Schreiber and colleagues (Siegel et al, 2000) showed that
mice transgenic for an activated oncogene developed
more, not less, tumors when pre-immunized with the onco-
gene, while Hanahan, Coussens and colleagues (Coussens
et al, 2000; Daniel et al, 2003) showed that a bystander
effect of anti-bacterial ab T cells was to promote local
inflammation that provoked tumor growth. Similarly, we
recently showed that the ab T cell response to chemically
induced SCC contains within it an activity that can promote
tumor progression (Girardi et al, 2003). Therefore, effective
clinical manipulation of the anti-tumor immune response
will require an improved understanding of which ab T cell
activities are protective and what their aggregate effects are
on tumor growth.
Transplantable tumor systems represent a powerful
means to establish such an understanding, because
identical tumor inocula can be used to compare immunity
in different groups of mice. To date, evidence from such
experiments points to the combined activity of tumor-
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infiltrating CD4þ and CD8þ T cells, although the respective
contributions of each subset appear to vary in different
studies (reviewed in Blankenstein, 2003). Thus, while rela-
tively few adoptively transferred tumor antigen-specific CD8þ
T cells were sufficient to eradicate established transplanted
tumors (Hanson et al, 2000; Klein et al, 2003), production of
interferon (IFN)g by CD4þ T cells appeared to be a critical
effector mechanism against transplanted (Mumberg et al,
1999; Qin and Blankenstein, 2000) and chemically induced
SCC (Kaplan et al, 1998; Qin et al, 2002). Moreover, recent
data have highlighted that the establishment of effective
CD8þ T cell memory requires CD4þ T cells (Shedlock and
Shen, 2003; Sun and Bevan, 2003).
To examine this issue further, we have identified the
components of the ab T cell response that are protective
against the widely used transplantable SCC line, PDV
(Fusenig et al, 1978; Diaz-Guerra et al, 1992). Moreover, we
have examined how tumors growing in situ in the presence or
absence of such components may differ from those growing
in immunocompetent mice. Collectively, the data support the
view that effective anti-tumor activities are an aggregate of
CD8þ and IFNg-producing CD4þ cells. The most overt
effects of these components on tumor growth in situ are to
provoke overt discrete areas of tumor necroses and to
decrease the stromal bed. Tumors growing in the presence
of any of these components also show reduced expression
of Rae-1, a ligand for the activating NK receptor, NKG2D.
Results
ab T cell response to PDV tumor development in C57BL/6
mice Following intradermal injection of 106 PDV cells into
each of the bilateral flanks (i.e., two sites per mouse) of 25
C57BL/6 mice, tumors developed in only 12.0% (3 of 25) of
mice in only 10.0% (5 of 50) of sites. Histologic examination
of the PDV tumors showed features diagnostic of well-
differentiated cutaneous SCC (Fig 1a). When 12 of the mice
Figure 1
Both CD4þ and CD8þ T cells are required for optimal response to PDV SCC. (a, panels i and ii) Intradermal injection of C57BL/6 mice with
1  106 PDV cells may give rise to tumors that histologically resemble human SCC in that each exhibit infiltration of stroma by irregularly shaped,
branching neoplastic lobules composed of keratinocytes with enlarged atypical nuclei and premature cornification (scale bar¼0.5 mm). (b) TCRb/
recipients were challenged with PDV tumor cells 4 d after intravenous administration of unsorted or negatively depleted SLN cells from
immunoprotected (‘‘immune’’) or ‘‘naı¨ve’’ B6 mice. The immune, but not naı¨ve, cells transferred anti-tumor immunity as evidence by abrogation of
tumor growth (panel i). If the cells from immune mice however were first depleted of CD4þ cells (CD4–, panel ii), CD8þ cells (CD8, panel iii), or both
(CD4CD8, depicted in both panels ii and iii), then tumor growth proceeded in most cases, demonstrating the dependence on both CD4 and CD8 T
cells for optimal anti-tumor immunity. (c) SLN cells were plated at 1  105 cells per well, in duplicate. (C, panel i) Numbers of spots/well, indicative of
IFNg secretion, were markedly higher for SLN cells isolated from immune mice than for naı¨ve C57BL/6 mice when in the presence of either irradiated
cultured PDV cells (po0.001) or freeze–thaw lysates of freshly isolated PDV tumor cells (po0.001). Wells containing PDV cells or lysates alone
showed no spots, and wells containing immune or naive T cells alone with 2 mg per mL concanavalin A showed 4500 spots (data not shown).
(c, panel ii) In an independent experiment, SLN cells from immune mice were plated at 1  105 cell equivalents per well, in duplicate. Wells
containing CD4þ T cells (i.e., unsorted and singly depleted of CD8þ cells (CD8)) demonstrated the ability to produce more spots (indicative of IFNg
secretion) in the presence of irradiated PDV cells, when compared with wells not containing CD4þ Tcells (i.e., singly depleted of CD4þ cells (CD4),
po0.001; or doubly depleted of CD4þ and CD8þ cells (CD4CD8), po0.001). Error bars represent SEM.
700 GIRARDI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
that failed to develop tumors at either site were re-
challenged with a 10-fold larger inoculum of PDV cells, all
were resistant to tumor formation, consistent with their
development of immunological memory. By contrast,
inoculation of 106 PDV cells per site led to tumor formation
in 15 of 15 C57BL/6 TCRb/ mice (that lack ab T cells) and
5 of 5 C57BL/6 TCRb/d/ mice (that lack ab and gd T
cells (Table I)). Furthermore, those relatively rare tumors that
developed in immunocompetent C57BL/6 mice did so with
a tumor latency (i.e., time from injection to development of
palpable tumors) of 3–8 weeks (mean 5.3 weeks), whereas
tumors in TCRb/ and TCRb/d/ mice all developed in
2–3 weeks (mean 2.3 and 2.2 wk, respectively).
To confirm that the enhanced tumor susceptibility of
TCRb/ mice reflected the absence of ab T cells, naı¨ve
TCRb/ mice were intravenously reconstituted with SLN
mononuclear cells from either naı¨ve C57BL/6 mice or
immunoprotected C57BL/6 mice (i.e., those demonstrating
resistance to prior PDV challenge). Four days later, the mice
were challenged with PDV tumor cells in the bilateral flanks
(two sites per mouse; 1  106 PDV cells per site). Whereas 4
of 4 TCRb/ mice receiving 10  106 SLN cells from naı¨ve
mice developed SCCs in 8/8 sites, no tumor developed in
TCRb/ mice receiving 10  106 SLN cells from immuno-
protected mice (Table II). Moreover, some protection was
afforded by adoptive transfer of as few as 1  106 SLN cells
from immunoprotected mice (Table II). These data are
consistent with a previous report that the T cell response
to PDV is dominated by ab T cells, rather than gd T cells
(Girardi et al, 2001).
To delineate which abþ T cells were important for anti-
tumor protection, TCRb/ mice were inoculated with
10  106 ‘‘cell equivalents’’ (see Materials and Methods) of
CD4þ , CD8þ , or CD4CD8 (double negative) SLN cells
from immunoprotected donors, obtained by selective
depletion of SLN cells using antibody-coated beads. The
resistance of these mice to challenge 4 d later with PDV
cells was compared with the full resistance of mice
receiving unsorted SLN cells from immunoprotected mice,
and the full susceptibility of mice receiving unsorted SLN
cells from naı¨ve mice (Fig 1bi ). All mice receiving unsorted
SLN cells from naı¨ve mice or double negative SLN cells
from immunoprotected donors succumbed to tumors (Fig
1b). Conversely, either CD4þ - or CD8þ -depleted SLN cells
from immunoprotected donors conferred partial resistance,
as evidenced by substantially diminished tumor growth rate
(Fig 1bi and ii ). Nonetheless, at 8 wk, the number of sur-
viving mice, the tumor incidence for each group (four mice;
eight sites per group), and the sizes of the tumors that
developed collectively indicated that inoculation of immune
SLN cells depleted of either CD4þ or CD8þ Tcells provided
markedly less protection than non-depleted inocula. In sum,
while neither CD4þ nor CD8þ T cells are absolutely essen-
tial for tumor protection, both contribute substantially to the
anti-tumor response.
Consistent with reports that CD4þ T cells contribute to
anti-tumor responses via IFNg production (Mumberg et al,
1999), SLN cells from immunoprotected mice but not naı¨ve
mice were shown by ELISpot assay to produce IFNg in
response to irradiated PDV cells (Fig 1c). Moreover, by de-
pleting SLN cells of CD4þ or CD8þ T cells, IFNg production
was attributable to CD4þ T cells, not CD8þ T cells.
T cell response to PDV tumor development in mutant
mice To confirm independently the involvement of CD4þ T
cells, CD8þ T cells, and IFNg in the immune protection of
C57BL/6 mice against PDV, tumor susceptibility was
assessed in CD4/ mice, b2m
/ mice (that are devoid of
CD8þ T cells because such cells cannot be positively
selected by a thymus lacking most MHC Class I molecules),
and IFNg/ mice. Relative to normal C57BL/6 controls
(N¼15 mice; 30 sites), all mutant mice (N¼8 mice; 16 sites)
rapidly developed tumors (Fig 2). At 24 days post-challenge,
tumor-site incidence was 93.8% in IFNg/ and b2m
/
mice, and 80.0% in CD4/ mice, compared with 20% in B6
controls and 100% in TCRb/ mice. Moreover, the mean
tumor size (scoring only sites with tumors) was significantly
smaller in C57BL/6 mice (18.3  5.1 mm2) compared with
CD4/ (33.2  4.7 mm2), b2m/ (53.3  12.2 mm2), and
IFNg/ mice (75.9  9.8 mm2) (po0.002 for C57BL/6
relative to IFNg/ mice).
Histologic differences in tumors growing in immuno-
competent versus immunodeﬁcient mice Tumors were
dissected from immunocompetent C57BL/6 mice and from
immunodeficient TCRb/ or IFNg/ mice, H&E stained,
and analyzed for morphologic differences by a pathologist
Table I. Increased tumor-site incidence and decreased tumor latency
in TCR mutant versus C57BL/6 mice following injection of PDV tumor cells
Mouse strain Tumor-mouse incidence Tumor-site incidence Mean tumor latencya
C57BL/6 12.0% (3/25) 10.0% (5/50) 5.3  2.4
TCRb/ 100.0% (15/15) 96.7% (29/30) 2.3  0.2c
TCRb/d/ 100.0% (5/5) 100.0% (10/10) 2.2  0.2c
atime (in weeks) to tumor area X16 mm2 post-injection of 1  106 PDV cells in mice that developed tumors.
bpo0.005 versus C57BL/6.
Table II. SLN cells from immunoprotected C57BL/6 (B6) do-
nors transfer protection to naı¨ve TCRb–/– recipients
Donor SLNa cell dose Recipient Tumor incidence
B6-naı¨veb 10  106 b/ 100% (4/4)
B6-immunec 10  106 b/ 0% (0/4)
B6-immune 1  106 b/ 33% (1/3)
aSLN¼pooled spleen and lymph node cells (10  106 cell equivalents).
bNaı¨ve¼donors not previously challenged with PDV.
cImmune¼ immunoprotected donors showing no evidence of tumor at
8þ weeks post-challenge with PDV.
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(EJG) in a blinded study. With 100% concordance, it was
possible for tumors to be assigned either to fully immuno-
competent hosts (C57BL/6), or to hosts that were partially
(IFNg/) or fully (TCRb/) immunodeficient. The assign-
ment was based on the observation that tumors growing in
TCRb/ or IFNg/ mice consistently demonstrated a rich
stroma and an absence of focal necrosis, relative to tumors
growing in C57BL/6 mice (Fig 3). This was confirmed by the
digital analysis of low-power images for the degree of
necrotic or cystic changes, and the quantitative analysis of
high-power images for the degree of stromal involvement.
NKG2D ligand expression by tumors growing in
immunocompetent and immunodeﬁcient mice One me-
chanism implicated in the anti-tumor response of cytolytic T
cells (CTLs) is their engagement via the activating receptor,
NKG2D, of ligands such as Rae-1 and MICA expressed by
mouse and human tumor cells, respectively (Groh et al,
1998; Girardi et al, 2001). Indeed, introduction of Rae-1 into
different tumor cell lines decreased their subsequent growth
in vivo by increasing CTL and/or NK-cell-mediated rejec-
tion (Cerwenka et al, 2001; Diefenbach et al, 2001). The
expression of ligands for NKG2D, however, has not
previously been examined during the growth of tumors in
immunocompetent versus immunodeficient mice. To test
this, Rae-1 RNA expression was assessed by quantitative
RT-PCR in three independent cultures of PDV cells, prior to
inoculation, and in PDV tumors directly explanted from
C57BL/6 or TCRb/ mice, CD4/, b2m
/, and IFNg/
mice (Fig 4). Whereas independent cultures of PDV cells
expressed comparable levels of Rae-1 (mean arbitrary
units¼1.9), those levels were consistently and substantially
reduced (mean arbitrary units¼0.2–0.5) in tumors har-
vested from mice with any one component of the anti-tumor
ab T cell response intact, i.e., CD4þ T cells, CD8þ T cells,
and IFNg. By contrast, Rae-1 levels were similarly reduced
in only two of eight tumors of comparable stages of growth
developing in TCRb/ mice lacking ab T cells. In the
remaining six tumors from TCRb/ mice, the mean
expression level in arbitrary units is 1.3, closer to the levels
expressed by PDV cells in vitro.
Discussion
For decades, organ transplant recipients treated with
immunosuppressive medications have provided a living
example of the importance of the immune response to skin
cancer (Fetscher et al, 1997; Cohn, 1998; Galvao et al, 1998;
Peto, 2001; Enzler et al, 2003). The markedly increased
incidence of SCC development and metastasis in this
population is consistent with various models of anti-tumor
surveillance by lymphocytes, and supports a clinical
strategy of using immunotherapy to combat tumor growth.
Nevertheless, an aggregate protective effect of T cells on
tumor development has not always been evident in animal
models, and some immunotherapy protocols have shown
mixed results in the clinic (Pardoll, 2002; Kalos, 2003).
Whereas some investigators have used such data to
dispute the concept of tumor immunosurveillance, several
recent studies suggest that such data may be explained by
a multi-component immune response to tumor growth, in
which only some immunological activities are protective,
while others de facto promote tumor growth (Siegel et al,
2000; Daniel et al, 2003; Girardi et al, 2003). In some
respects, this may parallel the immune response to infection
that is now appreciated to comprise both immunoprotective
and immunosuppressive components (Belkaid et al, 2002).
This perspective suggests that each of these components
need to be better understood if a more reliable knowledge
of tumor immunology is to be developed. To this end, this
paper has sought to clarify which components of the ab T
cell response against SCC have protective potential, and to
demonstrate which aspects of tumor physiology may be
most susceptible to those activities.
CD8þ cytotoxic T cells, CD4þ T cells, and IFNg have
most commonly been implicated in tumor immunosurveil-
lance both in humans and in animal studies (Soiffer et al,
2003; Patel et al, 1994; Hung et al, 1998; Kaplan et al, 1998;
Marzo et al, 1999; Mumberg et al, 1999; Qin and
Blankenstein, 2000; Blankenstein and Qin, 2003). Indeed,
tumors have been reported to develop spontaneously in
IFNg/ mice (Shankaran et al, 2001). The results in this
study confirm the involvement of each of these components
in the response to PDV tumors that develop with strong
similarities to well-differentiated human SCC. This is con-
sistent with the paradigm that tumors are unlikely to be
vulnerable to a single immunological effector activity, e.g.,
cytolysis effects, anti-proliferative effects, or angiostatic
effects. To investigate this further, some specific effects of
the immune system on tumor growth were examined in this
study.
We show that tumors growing in the absence of all ab T
cells, or in the absence of a single active immunological
component (IFNg) were strikingly different from those
growing in their fully immunocompetent hosts. Consistently
Figure 2
Analysis in immune knockout mice confirms dependence on
multiple immune components for optimal anti-tumor immunity to
PDV SCC. Relative to normal C57BL6 wild-type (WT) controls, all
groups of mutant (CD4/, b2m
/, and IFNg/) mice developed
tumors rapidly after intradermal challenge with PDV cells, confirming
the dependence of an anti-tumor immune response on CD4þ T cells,
CD8þ Tcells, and IFNg, respectively (po0.01 for WT vsCD4/, b2m/,
or IFNg/).
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they displayed an enriched stroma and lacked the central
necrosis characteristic of tumors that are under full
immunosurveillance. Of note, the morphology of tumors
growing in fully immunodeficient TCRb/ mice was in-
distinguishable from that of tumors growing in partially im-
munodeficient IFNg/ mice. This suggests that IFNg plays
a major role in regulating the peri-tumor stroma, with
consequences for the viability of cells in the core of the
tumor. The observation that tumor cells themselves are
more susceptible to surveillance if they express the IFNg
receptor (Shankaran et al, 2001; Basco et al, 2002)
emphasizes the likelihood that the effects of IFNg are
pleiotropic (reviewed by Ikeda et al, 2002). However, among
these effects of IFNg, the data presented here support the
possibility of a direct angiostatic effect on endothelial cells
(Beatty and Patterson, 2000; Qin and Blankenstein, 2000).
Thus, it was reported that the immune response of mice
pre-immunized with irradiated tumor cells inhibited the
angiogenesis of transplanted tumors via an IFNg-dependent
mechanism (Qin and Blankenstein, 2000). The potential of
immunological effector mechanisms to target non-trans-
formed stromal cells that support tumor development is
important, because such cells, unlike malignant cells, do
not have intrinsic chromosomal instability and are therefore
unlikely to evade the immune surveillance. Indeed, angio-
static targeting of stromal cells may yet prove to be a
common feature of immune responses against tumors,
pathogens, and allografts.
By contrast to their indistinguishable morphology, tumors
growing in TCRb/ mice and IFNg/ mice show distinct
expression patterns of the NKG2D ligand, Rae-1. Because
tumors with similar morphologies (from TCRb/ and IFNg/
mice) display different Rae-1 expression, while tumors with
different morphologies (from C57BL/6 and IFNg/ mice)
display similar Rae-1 expression, it is clear that the
differences in Rae-1 expression do not segregate with the
peri-tumor stroma. Most likely, these differences reflect an
altered expression of Rae-1 on the tumor cells themselves;
however, this would be difficult to establish experimentally
since the harsh disaggregation techniques that would be
required to separate tumor cells from supporting stroma are
likely to perturb the expression of molecules known to be
stress-responsive. Irrespective of the precise source of
Rae-1 expression in the tumors, the pattern is consistent: all
Figure 3
Tumors growing under immunocompetency
display focal necrosis and a decreased
stromal bed relative to tumors growing in
the absence of ab T cells or IFNc. Focal
necrosis (a) and tumor stroma area (b) were
calculated as a percentage of tumor area after
analysis of low-power and high-power histologic
images of tumors growing in wild-type (WT),
TCRb/, and IFNg/ mice (error bars repre-
sent SEM; po0.05, po0.01). (c, panels i
and ii) WT tumors typically exhibited foci of
necrosis (N) and cystic changes at scanning
magnification (representative section, 2  ) and
a paucity of stoma (S) at high magnification
(representative section, 20  ), relative to tumor
cells (T). By contrast TCRb/ and IFNg/
tumors showed little or no necrotic/cystic
change (2  ) and the presence of abundant
stroma with prominent vasculature (20  )
(scale bar¼1.0 mm for panel i, 0.025 mm for
panel ii). (c, panel iii) For the quantification
analysis shown in a and b, images were con-
verted to gray scale. For low-power images,
tumor regions were converted to black via
thresholding in the curves function, and necro-
tic/cystic regions were similarly converted to
white. For high-power images, only non-necro-
tic regions were utilized. Tumor regions were
converted to black and the stomal/vascular
compartment was converted to white. The
percentage of black and of white pixels was
then calculated for each image.
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tumors growing in hosts with any immunologically active
component (C57BL/6, CD4/, b2m
/, IFNg/ mice) show
substantially downregulated expression compared with
PDV cells prior to inoculation. By contrast, there is only
rare and less substantial downregulation in mice completely
lacking all ab T cells. The reduced expression of the NKG2D
ligand, Rae-1, in tumors developing in C57BL/6 mice is
consistent with tumor editing imposed by CD8þ T cell
surveillance, and with the reports that experimentally
imposed expression of Rae-1 in different tumor cell lines
increased their rejection in vivo (Cerwenka et al, 2001;
Diefenbach et al, 2001). The fact that Rae-1 expression was
also reduced in tumors growing in b2m
/ mice that lack
CD8þ CTLs is consistent with the fact, shown here, that the
anti-tumor T cell response is multi-faceted. Thus, tumors
still grow at a reduced rate in b2m
/ mice relative to their
growth in fully ab T cell-deficient mice, and the strong
possibility exists that IL2-producing CD4 ab T cells promote
the capacity of other cytolytic components (e.g., gd cells) to
counter tumor growth.
The inverse correlation of Rae-1 expression and the
host’s immunocompetence is consistent with the prospect
that by increasing NKG2D-ligand expression, immunologi-
cal attention may be focussed onto a developing tumor. In a
report that might seem to contradict the results reported
here, sustained expression of MICA, a human MHC Class IB
ligand for NKG2D, was observed to downregulate respond-
ing T cells or NK cells (Groh et al, 2002). A notable feature
however of that study was the evidence that sustained
MICA expression correlated with the capacity of tumors to
secrete the protein, which thereby can act as a molecular
decoy, binding NKG2D with no stimulatory consequence.
Thus, rather than being contradictory, both sets of experi-
ments highlight the importance of NKG2D ligands in
characterizing tumor growth. By further analysis of the
growth of carcinomas in immunocompetent and immuno-
deficient hosts, as described here, it should be possible to
identify the means and kinetics by which NKG2D ligand
expression can be regulated within tumor masses devel-
oping in vivo, and whether or not the modulation of NKG2D
ligand expression is of equivalent significance at different
stages of tumor development. One would expect that such
information might be useful for the further development and
application of improved immunotherapy modalities.
Materials and Methods
Animals TCRb/ (Mombaerts et al, 1992), TCRb/d/ (Mom-
baerts et al, 1992; Itohara et al, 1993), IFNg/ (Dalton et al, 1993),
b2-microglobulin (b2m)
–/– (Koller et al, 1990), and CD4/ (McCar-
rick et al, 1993) mice (previously backcrossed 10þ generations
onto C57BL/6 (B6)), and wild-type B6 mice were purchased from
Jackson Laboratories (Bar Harbor, Maine) and maintained as local
colonies under pathogen-free conditions in micro-isolator cages
with autoclaved food. All of the in vivo studies performed were
approved by the Yale Animal Use and Care Committee.
Cell culture The PDV keratinocyte tumor cell line, which grows as
an adherent squamoid monolayer in culture, was originally derived
by single exposure of normal keratinocytes to the carcinogen 7,12-
dimethyl-benzanthracene (DMBA). Molecular analysis has identi-
fied a mutation in codon 61 of the H-ras gene (Diaz-Guerra et al,
1992). Intradermal injection of 1  106 PDV cells into C57BL/6
mice had previously been demonstrated to result in tumor
development in approximately 10%–20% of injection sites (Caulin
et al, 1993; Girardi et al, 2001). PDV cells were maintained in
complete RPMI (CRPMI; RPMI 1640; Invitrogen, Palo Alto, Cali-
fornia) containing 10% fetal bovine serum (FBS), 2 mM glutamine,
100 mM non-essential amino acids, 1 mM sodium pyruvate, 40 M
Hepes buffer, 5  105 M 2-mercaptoethanol, and antibiotics.
Isolation of spleen and lymph node (SLN) cells Single-cell
suspensions were prepared as previously described (Girardi et al,
1995). Briefly, SLN cells were gently pressed between the frosted
edges of two glass slides, releasing the cells into ice-cold Hank’s
balanced salt solution (HBSS) containing 4 mM Hepes buffer and
Figure 4
Expression of the NKG2d ligand Rae-1 in PDV tumors growing in normal versus immunodeficient mice. RNA expression was assessed by
quantitative RT-PCR in three independent cultures of PDV cells and in PDV tumors directly explanted from wild-type (WT), TCRb/, CD4/, b2m
/,
or IFNg/ mice. Quantification of Rae-1 expression is shown for each individual tumor in gray bars, and the mean of all tumors within a group in
black bars. Error bars represent the standard deviation of the mean. Tumors from TCRb/ mice expressed significantly higher levels of Rae-1 than
tumors from immunocompetent WT mice (po0.002).
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antibiotics. Cells were filtered through nylon mesh (Nytex cloth 88/
42; Tetko, Elmsford, New York) to remove debris and to give single-
cell suspensions. SLN cells were washed twice with HBSS before
and after lysis of red blood cells using Red Blood Cell Lysis Buffer
(Sigma, St Louis, Missouri) according to the manufacturer’s
directions. Cells were washed, counted, and resuspended at
appropriate concentrations in phosphate-buffered saline (PBS)
(Invitrogen) for adoptive transfer, HBSS for antibody depletion, or
CRPMI for ELISpot assay. For adoptive transfer experiments,
sorted or unsorted SLN cells were injected in 100 mL PBS at the
indicated concentrations into the tail vein of recipient mice.
PDV tumor challenge Cultured PDV cells were trypsinized (Caulin
et al, 1993) and washed in PBS three times, counted, and
resuspended in PBS before intradermal injection (i.e., raising a
bleb) of 1  106 cells per site via a 25-gauge needle. Mice were
observed approximately weekly for palpable tumors, which were
measured in two dimensions to determine tumor area. Mice were
euthanized when tumor size exceeded 100 mm2, or earlier if tumor
ulceration developed.
T cell subset depletion Negative depletion of T cell subsets was
performed using Dynal iron bead-conjugated anti-CD4þ and
CD8þ antibodies (Dynabeads, Dynal Biotech Inc., Lake Sucess,
NY), according to the manufacturer’s specifications. Briefly, the
desired amount of Dynabeads was transferred to a test tube that
was placed on a Dynal MPC magnet, and the fluid was removed
leaving the beads intact. The vial was removed from the magnet
and the beads were resuspended in 2 mL of HBSS, washed once
more, resuspended in HBSS, and mixed with lymphocytes at a
ratio of 4  107 beads per 1  107 cells, briefly vortexed, and
incubated for 20 min at 41C with gentle tilting and rotation on a
Dynal MX1 apparatus. For doubly depleted cells, both CD4þ and
CD8þ Dynabeads were added. After incubation, the tube was
placed in the Dynal MPC magnet for 2 min before the CD4þ - and/
or CD8þ - depleted supernatant cell suspension was removed,
centrifuged, and resuspended in PBS prior to intravenous injection
or ELISpot assay. For both the adoptive transfer and ELISpot assay
utilizing CD4- and/or CD8-depleted populations, ‘‘cell equivalents’’
were utilized, as previously described (Gocinski and Tigelaar, 1990).
ELISpot assay ELISpot was carried out as previously described
(White et al, 1999), with modifications noted here. Briefly, wells of
MultiScreen 96-well plates (Millipore Billerica, MA) were coated
with purified rat anti-mouse IFNg monoclonal antibody (mAb)
(Pharmingen, #R4-6A2) (BD Sciences, San Diego, CA) at 10 mg per
mL in PBS (75 mL per well) at 41C overnight, blocked with 5% FBS
in PBS at room temperature (RT) for 2 h, and then rinsed 3 times
with PBS. SLN cells were plated in the presence or absence of g-
irradiated (3000 rad) PDV target cells in a final volume of 200 mL per
well in CRPMI, and incubated at 371C and 5% CO2 overnight.
Wells were rinsed 5 times with 0.05% Tween-20 in PBS (PBS-T)
before the addition of 100 mL of 5 mg per mL biotinylated rat anti-
mouse IFNg mAb (Pharmingen, XMG1.2) in 5% FBS in PBS-T at RT
for 2 h. Wells were rinsed extensively with PBS-T, and then
incubated with peroxidase-labeled streptavidin (KPL) at 1/800 dil-
ution in PBS-T containing 5% FBS at RT for 30 min. Spots were de-
veloped using Sigma 3-amino-9-ethylcarbazole (AEC) substrate
with dimethylformamide (DMF) and 30% hydrogen peroxide for up
to 15 min, and visualized with an inverted-light microscope for
counting.
Quantitation of RNA expression Tumors were isolated, dis-
sected, and snap-frozen in LN2 before homogenization in TRIzol
(Invitrogen, Carlsbad, California) and total RNA extraction accord-
ing to the manufacturer’s instructions. RNAs were also prepared
from three independent cultures of PDV. For quantitation of Rae-1
expression, cDNAs were prepared using Superscript II RT
polymerase (Invitrogen), and PCRs were run in the ABI 7700
(Perkin-Elmer, Boston, Massachussets) using the following primers
and 50 FAM/30 TAMRA-labeled probes:
Rae-1 sense: 50-ATGGCCAAGGCAGCAGTG-30
Rae-1 antisense: 50-GGTCAAGTTGCACCTAAGAGAGTG-30
Rae-1 probe: 50-AACAGCTTCTGAATCATAAAATGATGGCG-
CTT-30
b-actin sense: 50-GTCATCACTATTGGCAACGAG-30
b-actin antisense: 50-CACTGTGTTGGCATAGAGGTC-30
b-actin probe: 50-CCATCATGAAGTGTGACGTTGACA-30.
Histologic analysis Tumors from each animal were fixed in
formalin, embedded in paraffin, and standard 5 mm histologic
sections were prepared. Slides were routinely stained with
hematoxylin and eosin (H&E) and with anti-CD31 (ABP method)
(DAKO Cytomation, Carpenteria, California). One of the authors
(EJG), a pathologist, examined each section blindly and performed
quantitative analysis of tumor necrosis and cystic change versus
stroma and vascular components. Low (2  )- and high (20  )-
magnification digital photographs of H&E-stained sections of each
tumor were analyzed quantitatively by the same pathologist via
Adobe Photoshop 7.0 for Macintosh (Adobe Systems Incorpo-
rated, San Jose, CA). Photos were converted to gray scale. For
low-power images, tumor regions were converted to black via
thresholding in the curves function, and necrotic and/or cystic
regions were similarly converted to white. For high-power images,
only non-necrotic regions were utilized. Tumor regions were
converted to black and the stromal/vascular compartment was
converted to white. The percentage of black and of white pixels
was then calculated for each image.
Statistics Statistical significance was evaluated by the two-tailed,
unpaired Student’s t test, or non-parametric analysis if standard
deviations were significantly different between the two compared
groups.
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